Sector Update: Healthcare Shares Lower Pre-Market; Vertex Sinks On Phase 3 Study of Ivacaftor

By
A A A

Healthcare stocks:

JNJ: -0.03%

PFE: -0.26%

ABT: flat

MRK: -0.74%

AMGN: -0.03%

Healthcare shares are generally lower in pre-market trade.

Vertex ( VRTX ) shares are down 4% after it said data from a Phase 3 study of ivacaftor in 69 people 6 years of age and older with cystic fibrosis ( CF ) who have the R117H mutation did not meet the company's primary endpoint.

And, pSivida Corp. ( PSDV ) late yesterday said its licensee Alimera Sciences ( ALIM ) has entered into labeling discussions with the U.S. Food and Drug Administration (FDA) for ILUVIEN.

PSDV is up 64% at $4.87 pre-market; ALIM is up 101% at $5.14. As a result, both companies' participation in the January 2014 Dermatologic and Ophthalmic Advisory Committee meeting is no longer necessary.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: ALIM , CF , PSDV , VRTX

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Stocks

Referenced

100%
86%
100%
100%

Most Active by Volume

55,414,702
  • $15.38 ▼ 0.39%
38,503,210
  • $66.34 ▲ 2.26%
36,466,704
  • $8.36 ▼ 9.52%
35,253,294
  • $26.55 ▲ 1.34%
32,752,347
  • $6.55 ▲ 1.87%
31,778,001
  • $95.22 ▲ 0.19%
28,396,556
  • $51.49 ▼ 0.62%
23,800,987
  • $42.09 ▲ 0.97%
As of 7/11/2014, 04:03 PM